Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Regen BioPharma (RGBP) over the last 12 years, with Q3 2025 value amounting to $85967.0.

  • Regen BioPharma's Interest Expenses rose 32848.53% to $85967.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $132934.0, marking a year-over-year increase of 6614.05%. This contributed to the annual value of $158286.0 for FY2025, which is 11849.13% up from last year.
  • Latest data reveals that Regen BioPharma reported Interest Expenses of $85967.0 as of Q3 2025, which was up 32848.53% from $24638.0 recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's Interest Expenses registered a high of $117984.0 during Q3 2021, and its lowest value of $74.0 during Q1 2021.
  • In the last 5 years, Regen BioPharma's Interest Expenses had a median value of $20063.0 in 2024 and averaged $28745.6.
  • Per our database at Business Quant, Regen BioPharma's Interest Expenses tumbled by 9990.98% in 2021 and then skyrocketed by 5741486.49% in 2022.
  • Over the past 5 years, Regen BioPharma's Interest Expenses (Quarter) stood at $35010.0 in 2021, then tumbled by 50.42% to $17359.0 in 2022, then rose by 2.45% to $17784.0 in 2023, then soared by 42.56% to $25352.0 in 2024, then soared by 239.09% to $85967.0 in 2025.
  • Its Interest Expenses was $85967.0 in Q3 2025, compared to $24638.0 in Q2 2025 and $22329.0 in Q1 2025.